Combined with our findings that NRF2 modulation more greatly affected MDA-MB-231 cells, which exhibit higher RhoA expression, we inferred that RhoA may be a key factor in the NRF2 deficiency-mediated inhibition of breast cancer cell proliferation and metastasis. This evidence concerns the gene RHOA and breast carcinoma.